Amundi’s Immunome IMNM Stock Holding History

Amundi’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-92	Closed	-$574	–	1907
2025 Q1	$574	Buy	92 +14	+18%	+$134	﹤0.01%	2119
2024 Q4	$831	Buy	+78	New	+$943	﹤0.01%	2046

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Amundi's IMNM Position: Q2 2025 in Review

Amundi sold out of Immunome (IMNM) in Q2 2025, closing a stake of 92 shares — an estimated $574 sold.

Amundi first reported a position in IMNM in Q4 2024 and held it in 2 quarters. The position peaked at $831 in Q4 2024. 142 funds tracked by Wall St. Rank hold IMNM as of Q2 2025.

Amundi reported no remaining Immunome position as of Q2 2025 after selling out during the quarter.
Amundi sold 92 Immunome shares in Q2 2025, an estimated $574.
Amundi first reported a position in Immunome in Q4 2024 and held it in 2 quarters.
Amundi's Immunome position peaked at $831 in Q4 2024.
142 funds tracked by Wall St. Rank held Immunome as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.